Chemical Biology Consortium

The Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program brings together chemical biologists and molecular oncologists from government, industry, and academia to address unmet needs in therapeutic oncology. Members of the consortium contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology to advance early-stage drug discovery projects to selection of clinical candidates. Through the CBC, and with the interactions among the various Participants, the NCI’s drug discovery and development pipeline is active from target identification through proof-of-concept clinical trials.

The CBC operates as a collaborative network (managed by Frederick National Laboratory for Cancer Research) of 19 Institutes with drug discovery expertise and dedicated scientists from a wide range of disciplines who together support the advancement of NExT discovery projects and provide scientific leadership to project teams. With a blend of premier universities, non-profit research institutes and focused Contract Research Organizations, the CBC offers a complete set of technologies to facilitate the successful progression of discovery projects.